ArticleOncology and therapy2026

Real-World First-Line Treatment Characteristics and Physician Drivers in Advanced/Metastatic Non-Small Cell Lung Cancer, PD-L1 ≥ 50%, and without Actionable Genomic Alterations.

Dwight H Owen et al.PubMed ↗Publisher ↗

No numbers read from the abstract.